Research article summary (published 28 May 2006):

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Full Abstract

OBJECTIVE: To identify, review, and analyze studies comparing atomoxetine with psychostimulants with the intent of determining the role of atomoxetine in the pharmacologic management of attention deficit/hyperactivity disorder (ADHD). DATA SOURCES: Primary, review, and meta-analysis articles were identified by a MEDLINE search (1966-December 2005). MeSH headings used in the search include: attention deficit/hyperactivity disorder, ADHD, atomoxetine, stimulants, psychostimulants, methylphenidate, and amphetamine salts. Relevant data presented at professional meetings that we attended were also identified. STUDY SELECTION AND EXTRACTION: All clinical studies comparing atomoxetine with psychostimulants, regardless of study design, were evaluated. Relevant efficacy and safety data from these studies were included in the discussion. DATA SYNTHESIS: At time of writing, 5 head-to-head trials had compared psychostimulants and atomoxetine in the treatment of ADHD. No significant difference between atomoxetine and methylphenidate immediate-release were found on the ADHD Rating Scale total score. Osmotic oral release system (OROS) methylphenidate showed significantly greater improvement at weeks 1 and 2, and significantly more patients treated with OROS methylphenidate were classified as responders. Patients on both atomoxetine and mixed amphetamine salts extended-release (MAS XR) showed significant improvements at endpoint over baseline; however, Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) scores were significantly better with MAS XR. Tolerability was similar between atomoxetine and stimulant medications. CONCLUSIONS: Based on available evidence, psychostimulants are regarded as first-line pharmacologic treatment for children and adolescents with ADHD, as the efficacy and safety of these agents have been well established based on clinical trials and extensive naturalistic use. Adverse effects in some patients and abuse potential have led to the search for new treatments. Atomoxetine represents an alternative treatment for ADHD and is unlikely to be associated with abuse; however, long-term safety data are needed to further establish its place in therapy.

Author information

Author/s: Gibson, Aaron P (AP); Bettinger, Tawny L (TL); Patel, Nick C (NC); Crismon, M Lynn (ML);

Affiliation: College of Pharmacy, The University of Texas at Austin, 78712, USA.

Journal and publication information

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: The Annals of pharmacotherapy (Ann Pharmacother), published in United States. (Language: eng)

Reference: 2006-Jun; vol 40 (issue 6) : pp 1134-42

Dates: Created 2006/06/07; Completed 2006/08/23; Revised 2007/11/15;

PMID: 16735655, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adrenergic Uptake Inhibitors - adverse effects; therapeutic use Attention Deficit Disorder with Hyperactivity - drug therapy; psychology Central Nervous System Stimulants - adverse effects; therapeutic use Child

Clinical Trials as Topic Humans Propylamines - adverse effects; therapeutic use Substance-Related Disorders

Associated Chemicals: Adrenergic Uptake Inhibitors (0) ; Central Nervous System Stimulants (0) ; Propylamines (0) ; atomoxetine (83015-26-3)

Related articles

These are the highest related articles currently in the database:

• Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects. 30 Jan 2007
• Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. 30 Mar 2008
• Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. 30 Dec 2006
• Improving decision making in the treatment of ADHD. 30 May 2008
• [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder] 29 Sep 2004
• Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. 30 Mar 2006
• Acute suicidality after commencing atomoxetine. 29 Sep 2008
• Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence. 30 Dec 2007
• Non-stimulant trials of adult ADHD. 30 Mar 2007
• Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD. 29 Jun 2007

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.